- Home
- KNSA vs LAZ Comparison
KNSA vs LAZ Comparison
Compare KNSA & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | LAZ |
|---|---|---|
| Founded | 2015 | 1848 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | KNSA | LAZ |
|---|---|---|
| Price | $56.40 | $44.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $60.86 | $52.75 |
| AVG Volume (30 Days) | 800.5K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.21% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | 0.27 | ★ 0.91 |
| Revenue | $677,564,000.00 | ★ $3,186,466,000.00 |
| Revenue This Year | $37.48 | $13.36 |
| Revenue Next Year | $17.87 | $13.72 |
| P/E Ratio | $211.00 | ★ $20.25 |
| Revenue Growth | ★ 60.09 | 1.48 |
| 52 Week Low | $25.71 | $38.67 |
| 52 Week High | $57.27 | $58.75 |
Technical Indicators
Market Signals| Indicator | KNSA | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 42.50 |
| Support Level | $40.67 | $38.84 |
| Resistance Level | N/A | $52.19 |
| Average True Range (ATR) | 2.32 | 2.08 |
| MACD | 1.32 | -0.39 |
| Stochastic Oscillator | 95.15 | 6.84 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About LAZ Lazard Inc.
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.